Business
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harbori
About this update from Revolution Medicines, Inc.
[{"type":"image","alt":"Revolution Medicines, Inc.","displaySize":"","headline":null,"caption":"Revolution Medicines, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3a1eQ7JWfrr05E5mKs8MOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this year","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutation","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":590,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2025, and provided an update on corporate progress.","length":346,"tagName":"p"},{"type":"text","content":"“We made substantial clinical progress over the past year continuing to advance our broad portfolio of RAS(ON) inhibitors across multiple tumor types and disease settings,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “Our focus remains on executing high-quality clinical programs and leveraging our innovation platform to discover and develop potentially ground...